How can our industry address the root causes for the current cancer drug shortages, and how can we prepare and avoid these shortages? Anshul Mangal, President of Project Farma and Precision ADVANCE, sat down with PharmExec.com to share answers.
Despite innovation to date in gene therapy, safety concerns with adeno-associated virus (AAV) vectors and uneasiness around cost and affordability has brought into focus the need for even more advancement in the field. In this Pharma Live article, Precision’s Phil Cyr discusses some of the innovations that are occurring to address these issues.
Flow cytometry is a powerful tool in clinical trials as a platform for monitoring immune cells of interest. But how do you ensure a blood sample gets from draw to analysis and how do you choose the right sample type to preserve viability and function? Learn how in our latest blog.
Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision’s Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.
Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.
After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.
New study demonstrates the feasibility of systematically integrating long-term survival estimates obtained from a formal expert elicitation study with empirical clinical trial data through a case study.
Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. In this article for PM360 Magazine, Precision’s Anshul Mangal explores the breakthroughs taking place in autologous cell therapies, non-viral delivery methods, and gene editing technologies that may improve patient access for life-saving treatments.
Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.
Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.